MasterBrand (MBC) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Welcome to Master Brands First Quarter twenty twenty five Earnings Conference Call. During the company's prepared remarks, all participants will be in a listen only mode. Following management's closing remarks, callers are invited to participate in a question and answer session. Please note that this conference call is being recorded. I would now like to turn the call over to your host, Farron Pollak, Vice President of Investor Relati ...

Masimo (MASI) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and welcome to Masimo's First Quarter twenty twenty five Earnings Conference Call. The company's press release is available at www.masimo.com. At this time, all lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I'm pleased to introduce Eli Hammerman, Masimo's Vice President of Business Development and Investor Rela ...

Financial Data and Key Metrics Changes - Third quarter revenues reached $58.4 million, representing a 21% year-over-year increase [7][18] - Adjusted EBITDA increased by 27% year-over-year to $6.4 million, with an adjusted EBITDA margin improvement of 50 basis points to 11% [10][23] - Gross margin improved to 81%, up from 78.9% in the prior year [21] - Adjusted non-GAAP net income was $3.5 million, or $0.26 per fully diluted share, compared to $2.8 million, or $0.21 per fully diluted share in the prior year [22] Business Line Data and Key Metrics Changes - The MINDBODY GLP-one system was the primary growth driver, with U.S. revenues growing by 31% year-over-year [8] - Active accounts in the Americas increased by 17% year-over-year, with a 13% increase in independent consultants and a 19% increase in customers [11] - Subscription orders showed positive trends, with 85% of new customers opting for subscriptions during the quarter [30] Market Data and Key Metrics Changes - Revenue in the Americas increased by 29.5% to $48.2 million, while revenue in Asia Pacific and Europe decreased by 7.2% to $10.2 million [19][20] - Japan's revenue increased by 2.7% on a constant currency basis, reflecting the launch of the MINDBODY system [20] Company Strategy and Development Direction - The company is focused on enhancing digital capabilities, building brand awareness, and maintaining strong profitability metrics while funding growth initiatives [15] - The EVOLVE compensation plan aims to provide consultants with multiple income streams and support their business growth [13] - The company plans to complete the global rollout of the MINDBODY system in remaining markets later this year [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the MINDBODY system's potential for long-term transformational impact on the business [16] - The company anticipates fiscal year 2025 revenue to be between $228 million and $235 million, representing a 16% increase year-over-year at the midpoint [25] - Management acknowledged challenges in international markets but remains optimistic about future growth opportunities [38] Other Important Information - The company held its annual global convention, revealing positive results from a clinical study on the MINDBODY system, which showed an average increase of GLP-one levels by over 200% [14][15] - A quarterly cash dividend of $0.45 per share was announced, totaling approximately $600,000 [25] Q&A Session Summary Question: What percentage of new customers are coming in on subscription? - Management noted a slight decline in active accounts sequentially, but subscription rates increased, with 85% of new customers on subscriptions during the quarter [30] Question: Are there more purchases in stacks versus standalone products? - Management confirmed that about 55% of revenue during the quarter was from standalone MINDBODY products, while 45% were from stacked purchases with other products [32] Question: What is the reason for the revenue outlook change? - Management indicated that the revenue reduction is due to both past results and anticipated results, with challenges from the initial product launch now resolved [36][38] Question: What have been the learnings about the MINDBODY product? - Management highlighted the importance of educating the sales force on the product's long-term health benefits rather than positioning it solely for weight loss [44][48]

LifeMD (LFMD) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon. Thank you for joining us today to discuss LifeMD's results for the first quarter ended 03/31/2025. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer and Mark Benethen, Chief Financial Officer. Following management's prepared remarks, we will open the call for a question and answer session. Before we begin, I would like to remind everyone that during this call, the company will make a number ...

Latham Group (SWIM) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good day, and welcome to the Latham Group Inc. First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press then 1 on your touch tone phone. To withdraw your question, please press then 2. Please note this event is being recorded. I would now like to turn the conference over to Ms. C ...

Klaviyo (KVYO) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Thank you. With that, I would like to turn the call over to Andrew Zilli, Vice President of Investor Relations. You may begin. Speaker1 Thanks. Speaker2 Good afternoon, and thanks for joining Klaviyo's first quarter twenty twenty five earnings call. Our earnings press release, investor presentation, SEC filings and a replay of today's call can be found on our IR website at investors.claviyo.com. With me on the call today are Andrew Bayal ...

Jazz Pharmaceuticals (JAZZ) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Jeff Macdonald - Executive director & IRBruce Cozadd - Chairman and Chief Executive OfficerRenée Galá - President & COORobert Iannone - Executive VP, Chief Medical Officer and Global Head of Research & DevelopmentPhilip Johnson - Executive VP & CFOJason Gerberry - MD & Equity ResearchMarc Goodman - Senior MD - NeuroscienceAnnabel Samimy - Managing DirectorAmy Li - SVP Equity ResearchAshwani Verma - Executive Dire ...

Jazz Pharmaceuticals (JAZZ) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to the Jazz Pharmaceuticals First Quarter twenty twenty five Webcast Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, Speaker1 there Speaker0 will be a question and answer session. Thank you. I would now like to ...

Jamf (JAMF) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Thank you for standing by, and welcome to JAMP's First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. If your question has been answered and you'd like to remove yourself from the queue, simply press 11 again. As a reminder, today's program is being recorded. And now I'd like to introduce your host for ...

Financial Data and Key Metrics Changes - Consolidated revenues for the first quarter of 2025 were $274.2 million, a decrease of 13% compared to $315.2 million in the prior year period [19] - Net loss attributable to common stockholders was $24.8 million or $1.89 per fully diluted share, compared to a net loss of $17.7 million or $2.21 per fully diluted share in the prior year [19] - Total adjusted EBITDA was $7.2 million, down from $12.8 million in the prior year period [19] Business Line Data and Key Metrics Changes - Infrastructure segment revenues decreased 14% to $264.9 million from $307.9 million in the prior year quarter, primarily due to project timing and size [20] - Life Sciences segment revenues increased 210% to $3.1 million from $1 million in the prior year quarter, driven by increased unit sales [22] - Spectrum segment revenues were $6.2 million, a slight decrease of $100,000 compared to the first quarter of 2024 [22] Market Data and Key Metrics Changes - DBM Global achieved revenues of $264.9 million and adjusted EBITDA of $16.7 million, with a gross margin improvement of approximately 110 basis points to 15.6% [7] - R2 tripled its year-over-year revenue to $3.1 million, with significant growth in North America [12] - The company is now serving 28 countries and has entered into distribution agreements in several European and South American countries [13] Company Strategy and Development Direction - The company is focused on addressing its capital structure and near-term debt maturities while leveraging valuable assets [6] - The strategic vision emphasizes maximizing the value of assets and exploring strategic alternatives [17] - The company is actively pursuing commercial opportunities in data casting and modernizing broadcasting capabilities [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute on strategic objectives and highlighted the strong backlog and robust pipeline for DBM [6][7] - The ongoing tariff situation is being monitored, with no material impact observed on DBM's business as of now [8] - The company remains optimistic about the market opportunity for R2 and the momentum experienced year over year [15] Other Important Information - As of March 31, 2025, the company had total principal outstanding indebtedness of $672 million, an increase from the previous year [25] - Cash and cash equivalents were $33.3 million, down from $48.8 million at the end of 2024 [24] Q&A Session Summary - There were no questions during the Q&A session, and the call concluded with management expressing satisfaction with the momentum to start the year [26][27]